Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-elderly vaccine response study of MenACWY-TT and Zostavax
NL-OMON47511Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Sep 2014
- Modality
- Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Meningococcal polysaccharide vaccine group W-135 and zoster vaccine, live in meningococcal disease and herpes zoster (HZ) (2 cohorts), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Meningococcal specific serum bactericidal antibody levels after MenACWY-TT vaccination and Varicella zoster virus memory T-cell responses after vaccination. Started Sep 2014; status: active, not recruiting.
02
Drugs
Meningococcal polysaccharide vaccine group W-135zoster vaccine, live
03
Conditions
meningococcal diseaseherpes zoster (HZ)
Beyond the preview
Go deeper on NL-OMON47511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47511.